HC Wainwright Increases Earnings Estimates for FocalTherics

FocalTherics (NASDAQ:FOCL – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of FocalTherics in a report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.71) per share for the year, up from their previous estimate of ($0.82). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for FocalTherics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for FocalTherics’ Q4 2026 earnings at ($0.16) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.43) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.21 EPS.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of FocalTherics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Mizuho started coverage on FocalTherics in a research report on Friday, July 17th. They set an “outperform” rating and a $15.00 price target on the stock. Weiss Ratings cut shares of FocalTherics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.67.

View Our Latest Stock Report on FocalTherics

FocalTherics Stock Performance

NASDAQ:FOCL opened at $3.53 on Tuesday. The stock’s 50-day moving average is $4.18. The company has a current ratio of 2.63, a quick ratio of 2.40 and a debt-to-equity ratio of 0.98. FocalTherics has a 52-week low of $1.92 and a 52-week high of $6.40.

FocalTherics (NASDAQ:FOCL – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.08. The company had revenue of $9.83 million during the quarter. FocalTherics had a negative net margin of 59.77% and a negative return on equity of 223.32%.

Insiders Place Their Bets

In related news, Director Lance Willsey purchased 50,000 shares of the stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $4.75 per share, with a total value of $237,500.00. Following the transaction, the director directly owned 1,291,780 shares of the company’s stock, valued at $6,135,955. This trade represents a 4.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Joshua Levine bought 10,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $213,750. The trade was a 28.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 116,000 shares of company stock valued at $551,000 over the last 90 days. 10.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On FocalTherics

A hedge fund recently bought a new stake in FocalTherics stock. Lido Advisors LLC acquired a new stake in FocalTherics (NASDAQ:FOCL – Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,654 shares of the company’s stock, valued at approximately $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

FocalTherics News Roundup

These are some of the FOCL news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.71 from $0.82 and its FY2027 estimate to a loss of $0.43 from $0.47. It also narrowed several quarterly loss forecasts. The firm maintained a Buy rating and a $10 price target, well above the $3.53 share price cited in the background. FocalTherics analyst coverage
  • Neutral Sentiment: A short-interest report states that short interest was zero shares as of November 10, despite describing it as a significant increase. If accurate, that indicates little reported short positioning, but the contradictory wording makes the data hard to interpret.
  • Negative Sentiment: HC Wainwright lowered its longer-term EPS forecasts for FY2029 (to $0.03 from $0.05) and FY2030 (to $0.21 from $0.25), tempering the improved near-term outlook. FocalTherics analyst coverage

About FocalTherics

(Get Free Report)

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

Read More

Earnings History and Estimates for FocalTherics (NASDAQ:FOCL)

Receive News & Ratings for FocalTherics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FocalTherics and related companies with MarketBeat.com's FREE daily email newsletter.